UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) ~~August~~January 723, ~~2025~~2026

Daxor Corporation

(Exact name of registrant as specified in its charter)

New York	811-22684	13-2682108
(State or other jurisdiction	(Commission	(IRS Employer
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
of incorporation)	File Number)	Identification No.)

107 Meco Lane, Oak Ridge, TN		37830
(Address of principal executive offices)		(Zip Code)

212-330-8500

Registrant’s telephone number, including area code

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.01 par value		DXR		Nasdaq

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Item 8.01 – Other Events

~~Daxor~~Attached ~~Corporation,~~hereto ~~the~~as ~~global~~Exhibit ~~leader in blood volume measurement technology, announces FDA 510(k) clearance for its next-generation rapid, portable lab-based Blood Volume Analysis (BVA) system~~99.1 ~~The~~is ~~new~~ Daxor ~~BVA™ device quantifies a patient~~Corporation’s ~~blood~~current ~~volume~~investor ~~against patient-specific norms, enabling precise care, significantly improving outcomes for millions of patients each year~~presentation.

The press release issued is attached to this filing as Exhibit 99.1

Item 9.01 Exhibits

(d)

Exhibits. The following exhibit is filed with this Current Report on Form 8-K:

No.		Description
99.1		~~Press~~Attached ~~release~~hereto ~~dated~~is ~~August~~an 7,investor ~~2025 – Daxor Corporation Receives FDA Clearance for New Rapid, Portable Lab-Based Blood Volume Analysis System~~presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	DAXOR CORPORATION
	(Registrant)
Date: August 7, 2025	By:	/s/ Robert J. Michel
Date: January 23, 2026	By:	/s/ Robert J. Michel
	Name:	Robert J. Michel
	Title:	Chief Financial Officer

Filing Compare · DAXOR CORP